Primary resistance or early disease progression (PFS < 3 months) to KRAS G12C inhibitors occurs in about 36% of patients who received sotorasib therapy, as shown in recently published data from the 2-year analysis of the CodeBreaK100 study in NSCLC (41). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.